- By insider

CEO of Alnylam Pharmaceuticals Inc (ALNY) John Maraganore sold 73,415 shares of ALNY on 11/22/2017 at an average price of $130.9 a share. The total sale was $9.6 million.

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes. Alnylam Pharmaceuticals Inc has a market cap of $12.32 billion; its shares were traded at around $132.85 with and P/S ratio of 168.16. Alnylam Pharmaceuticals Inc had annual average EBITDA growth of 18.10% over the past ten years.

• Warning! GuruFocus has detected 4 Warning Signs with ALNY. Click here to check it out.

• ALNY 15-Year Financial Data

• The intrinsic value of ALNY

• Peter Lynch Chart of ALNY

CEO Recent Trades:

• CEO John Maraganore sold 73,415 shares of ALNY stock on 11/22/2017 at the average price of $130.9. The price of the stock has increased by 1.49% since.

• CEO John Maraganore sold 74,000 shares of ALNY stock on 11/15/2017 at the average price of $126.86. The price of the stock has increased by 4.72% since.

Directors and Officers Recent Trades:

• Director Dennis A Ausiello sold 20,000 shares of ALNY stock on 11/02/2017 at the average price of $130. The price of the stock has increased by 2.19% since.

• EVP, R&D Akshay Vaishnaw sold 33,666 shares of ALNY stock on 10/30/2017 at the average price of $121.46. The price of the stock has increased by 9.38% since.

For the complete insider trading history of ALNY, click here

.This article first appeared on GuruFocus.

• Warning! GuruFocus has detected 4 Warning Signs with ALNY. Click here to check it out.

• ALNY 15-Year Financial Data

• The intrinsic value of ALNY

• Peter Lynch Chart of ALNY